Nintedanib

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — a move applauded by experts as they await the impact of the first-round of discounts anticipated next year.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

Amy Hajari Case, MD, FCCP, has been named chief medical officer of the Pulmonary Fibrosis Foundation, according to a press release.

Among patients with COVID-19 and acute respiratory failure, survival at 1 year was more likely if they received nintedanib or pirfenidone antifibrotics, according to results published in BMC Pulmonary Medicine.

Increased body surface area lowered the likelihood for nintedanib dose reduction/discontinuation among patients with fibrotic interstitial lung disease, according to results published in Respiratory Medicine.

In a study of patients with small cell lung cancer and idiopathic pulmonary fibrosis receiving carboplatin, etoposide and nintedanib, the primary endpoint was met, according to results published in Annals of the American Thoracic Society.

Among patients with progressive pulmonary fibrosis, taking nintedanib for 52 weeks lowered the degree of worsened dyspnea, fatigue and cough compared with placebo, according to results published in European Respiratory Journal.

HONOLULU — Treatment with nintedanib plus pirfenidone resulted in a similar frequency of adverse events as monotherapy among patients with idiopathic pulmonary fibrosis, according to a systemic review presented at the CHEST Annual Meeting.

HONOLULU — Risk for mortality and hospitalization did not differ between patients with idiopathic pulmonary fibrosis taking 100 mg or 150 mg nintedanib twice daily, according to a real-world analysis presented at the CHEST Annual Meeting.

Patients with systemic sclerosis-associated interstitial lung disease who receive nintedanib demonstrate a higher risk for malnutrition, compared with placebo, according to data published in Arthritis Care & Research.